Information Technology
New Report from Clarivate and Healthcare Executive Explores Mainland China's Biopharma Revolution and Increasing Global Influence
Over the past decade, Mainland China's biopharmaceutical sector has rapidly advanced to become a global leader in innovation, ranking among the top three for initial drug launches. Driven by reforms, increased investment, and progressive policies, the industry has reduced approval timelines, raised regulatory standards, and improved patient access to advanced therapies. Insights from the Institute for Scientific Information™ show that China's Gross Expenditure on Research and Development has grown 3.5 times over the past decade, outpacing growth rates in the UK and the U.S. These developments, combined with an evolving healthcare reimbursement system, have enabled both domestic and multinational companies to bring new therapies to market, benefiting millions of patients.
"Mainland China's ascent in the biopharma sector reflects the power of sustained investment and strategic reform. This report not only highlights the impressive achievements of the past decade but also underlines the far-reaching potential for Chinese biopharma companies to drive global medical innovation and enhance patient outcomes worldwide."
"The pharmaceutical industry is poised for significant and transformative changes in the upcoming decade, driven by heightened competition. Rapid innovation and intense competition have reshaped market dynamics, leading to more focused and sustainable growth. The report offers the industry a glimpse of how Chinese pharmaceutical companies can prioritize innovation and international expansion in the next decade."
"This report is an invaluable resource for global industry stakeholders. For pharma companies worldwide, it provides a timely understanding of Mainland China's biopharma landscape, covering the opportunities for international collaboration and the potential for accelerated market entry."
The report highlights Mainland China's regulatory advancements, rapid drug launch growth, and expanding domestic R&D role. Key updates include the National Reimbursement Drug List (NRDL), where systematic price negotiations have cut costs by 50-60%, improving access to innovative drugs. Additionally, Mainland China's share of global licensing and service deals has grown from 6.5% to nearly 9% since 2015, and the country now leads in publishing research and filing patents in key life sciences, underscoring its rising influence on the global industry.
With Mainland China's share of first-time global drug launches growing, and as new therapeutic areas advance,
provides timely, in-depth insights for international investors, multinational pharmaceutical companies, and healthcare stakeholders who seek to understand Mainland China's role in shaping the future of the biopharma landscape.
The report draws on comprehensive data and tools trusted by the global life sciences community, including Cortellis Competitive Intelligence , Cortellis Regulatory Intelligence ™, Disease Landscape & Forecast , Cortellis Deals Intelligence , Cortellis Clinical Trials Intelligence ™, Cortellis Product Intelligence ™, Real World Data and Analytics , Access and reimbursement payer studies , BioWorld ™, Web of Science ™ and Derwent Innovation ™ among others. Compiled by Clarivate analysts using data gathered prior to August 31, 2024 , this report reflects Clarivate's commitment to supporting drug, device, and medical technology lifecycles. By combining patient journey data, therapeutic insights, and AI-driven analytics, Clarivate enables evidence-based decisions that advance human health.
With media as the outpost, conference as the platform, live video broadcasting as the tool, and expert pharmaceutical industry observers and recorders as the living force, Healthcare Executive (E药经理人) brings the top consensus of entrepreneurs, scientists, and investors in the pharmaceutical industry together on the one hand, and on the other hand gathers multi-dimensional and multi-level resources from the whole industry chain. We are dedicated to providing in-depth professional communication opportunities and influential solutions for the whole industry chain in their whole life cycle. In this regard, we make connections with client requirements upstream and downstream and make preparations for the overseas strategy in their international programs.
Clarivate™ is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit www.clarivate.com
Catherine Daniel
Director, External Communications, Life Sciences & Healthcare
Clarivate
newsroom@clarivate.com
Source: Global Research Report: China's research landscape, ISI, Clarivate
View original content: https://www.prnewswire.co.uk/news-releases/new-report-from-clarivate-and-healthcare-executive-explores-mainland-chinas-biopharma-revolution-and-increasing-global-influence-302307326.html